Back to results
US 10,307,480 B2Granted
Anti-pro/latent-myostatin antibodies and uses thereof
AssigneeScholar Rock, Inc.
InventorsMichelle Straub, Dong Yun Lee, William K. McConaughy, Katherine Jane Turner, Nagesh K. Mahanthappa, Justin W. Jackson
Life of this patent
Estimating the term…
Abstract
Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
Claims19
An isolated antibody, or an antigen-binding fragment thereof, that specifically binds pro/latent Myostatin compared with mature Myostatin,
- wherein the antibody, or antigen-binding fragment thereof, comprises six complementarity determining regions (CDRs):
- CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3,
- wherein CDRH1 comprises a sequence that is at least 90% identical to a CDRH1 sequence as set forth as any one of SEQ ID NOs:
- 1, 2, 70, 71, and 77, or wherein CDRH1 comprises a sequence that is at least 90% identical to a CDRH1 sequence as set forth in any one of SEQ ID NOs:
- 65, 66, or 69,
- wherein CDRH2 comprises a sequence that is at least 90% identical to a CDRH2 sequence as set forth as any one of SEQ ID NOs:
- 4, 5, 72, and 78, or wherein CDRH2 comprises a sequence that is at least 90% identical to a CDRH2 sequence as set forth in any one of SEQ ID NOs:
- 65, 66, 67 or 69,
- wherein CDRH3 comprises a sequence that is at least 90% identical to a CDRH3 sequence as set forth as any one of SEQ ID NOs:
- 10, 73, 74, 75, 76, 79, and 80,
- wherein CDRL1 comprises a sequence that is at least 90% identical to a CDRL1 sequence as set forth as any one of SEQ ID NOs:
- 12, 13, 87, 88, 89, and 98, or wherein CDRL1 comprises a sequence that is at least 90% identical to a CDRL1 sequence as set forth in any one of SEQ ID NOs:
- 84 or 85,
- wherein CDRL2 comprises a sequence that is at least 90% identical to a CDRL2 sequence as set forth as any one of SEQ ID NOs:
- 18, 19, 90, 91, and 99, or wherein CDRL2 comprises a sequence that is at least 90% identical to a CDRL2 sequence as set forth in any one of SEQ ID NOs:
- 83, 84 or 86, and
- wherein CDRL3 comprises a sequence that is at least 90% identical to a CDRL3 sequence as set forth as any one of SEQ ID NOs:
- 22, 93, 94, 95, 97, 100, and 101.
15 more elements
A method of assessing a biological sample obtained from a subject having a myopathy, the method comprising:
- (a) preparing an immunological reaction mixture that comprises protein of a biological sample obtained from the subject and an antibody, or an antigen-binding fragment thereof that specifically binds latent Myostatin, wherein the antibody, or antigen-binding fragment thereof, comprises six complementarity determining regions (CDRs):
- CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3,
- wherein CDRH1 comprises a sequence that is at least 90% identical to a CDRH1 sequence as set forth as any one of SEQ ID NOs:
- 1, 2, 70, 71, and 77, or wherein CDRH1 comprises a sequence that is at least 90% identical to a CDRH1 sequence as set forth in any one of SEQ ID NOs:
- 65, 66, or 69,
- wherein CDRH2 comprises a sequence that is at least 90% identical to a CDRH2 sequence as set forth as any one of SEQ ID NOs:
- 4, 5, 72, and 78, or wherein CDRH2 comprises a sequence that is at least 90% identical to a CDRH2 sequence as set forth in any one of SEQ ID NOs:
- 65, 66, 67 or 69,
- wherein CDRH3 comprises a sequence that is at least 90% identical to a CDRH3 sequence as set forth as any one of SEQ ID NOs:
- 10, 73, 74, 75, 76, 79, and 80,
- wherein CDRL1 comprises a sequence that is at least 90% identical to a CDRL1 sequence as set forth as any one of SEQ ID NOs:
- 12, 13, 87, 88, 89, and 98, or wherein CDRL1 comprises a sequence that is at least 90% identical to a CDRL1 sequence as set forth in any one of SEQ ID NOs:
- 84 or 85,
- wherein CDRL2 comprises a sequence that is at least 90% identical to a CDRL2 sequence as set forth as any one of SEQ ID NOs:
- 18, 19, 90, 91, and 99, or wherein CDRL2 comprises a sequence that is at least 90% identical to a CDRL2 sequence as set forth in any one of SEQ ID NOs:
- 83, 84 or 86, and
- wherein CDRL3 comprises a sequence that is at least 90% identical to a CDRL3 sequence as set forth as any one of SEQ ID NOs:
- 22, 93, 94, 95, 97, 100, and 101;
- (b) maintaining the immunological reaction mixture under conditions that permit binding complexes to form between the antibody and a latent Myostatin;
- and
- (c) determining the extent of binding complex formation.
18 more elements
Dependencies are inferred from the claim text.